At Delee, we aim to radically change the way cancer is detected, monitored and treated. Through the development of the CytoCatchâ˘, which is a highly sensitive automated benchtop device, we have made possible to rapidly isolate and efficiently analyze circulating tumor cells from blood samples. This innovative technology enables not only the early detection of cancer, but also the continuous monitoring of the diseaseâs evolution and the effectiveness of therapies that are being administered; increasing the patientâs chances of defeating cancer.
No articles found.
Medigus is a medical device company specializing in developing minimally invasive ...
Medigus is a medical device company specializin...
Celsion Corporation is a fully integrated biopharmaceutical company focused on dev...
Celsion Corporation is a fully integrated bioph...
Tiziana Life Sciences is a dual-listed (NASDAQ:TLSA, AIM:TILS) clinical stage biot...
Tiziana Life Sciences is a dual-listed (NASDAQ:...
Eclipes Diagnostics develops CANABINOX, a handheld testing device that can accurat...
Eclipes Diagnostics develops CANABINOX, a handh...
Cytonics, founded in 2006, is a private research and development company focused o...
Cytonics, founded in 2006, is a private researc...
Cloud DX creates easy-to-use medical devices and mobile apps that help people get ...
Cloud DX creates easy-to-use medical devices an...
Histogenics historically focused on the development of restorative cell therapies,...
Histogenics historically focused on the develop...
Join the National Investor Network and get the latest information with your interests in mind.